Front Immunol. 2021 Apr 16;12:666233. doi: 10.3389/fimmu.2021.666233. eCollection 2021.
Roxane Elaldi 1 2, Patrice Hemon 3, Luciana Petti 1, Estelle Cosson 1, Belinda Desrues 4, Anne Sudaka 5, Gilles Poissonnet 2, Ellen Van Obberghen-Schilling 4, Jacques-Olivier Pers 3, Veronique M Braud 1, Fabienne Anjuère 1, Aïda Meghraoui-Kheddar 1
1 Université Côte d’Azur, CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
2 Institut Universitaire de la Face et du Cou, Nice, France.
3 U1227, LBAI, University of Brest, INSERM, CHU de Brest, Brest, France.
4 Université Côte d’Azur, CNRS, INSERM, iBV, Nice, France.
5 Centre Antoine Lacassagne, Anatomopathology Laboratory and Human Biobank, Nice, France.
The integrative analysis of tumor immune microenvironment (TiME) components, their interactions and their microanatomical distribution is mandatory to better understand tumor progression. Imaging Mass Cytometry (IMC) is a high dimensional tissue imaging system which allows the comprehensive and multiparametric in situ exploration of tumor microenvironments at a single cell level. We describe here the design of a 39-antibody IMC panel for the staining of formalin-fixed paraffin-embedded human tumor sections. We also provide an optimized staining procedure and details of the experimental workflow. This panel deciphers the nature of immune cells, their functions and their interactions with tumor cells and cancer-associated fibroblasts as well as with other TiME structural components known to be associated with tumor progression like nerve fibers and tumor extracellular matrix proteins. This panel represents a valuable innovative and powerful tool for fundamental and clinical studies that could be used for the identification of prognostic biomarkers and mechanisms of resistance to current immunotherapies.